Genentech, Inc. Announces June 2 Webcast Discussion Of Lucentis Data Presented At The 2006 Retinal Physician Symposium

SOUTH SAN FRANCISCO, Calif., May 19 /PRNewswire-FirstCall/ -- Genentech, Inc. invites investors, the media and the general public to listen to an audio webcast discussing the Lucentis Phase IIIb PIER data which is to be presented at the 2006 Retinal Physician Symposium in the Bahamas on June 2, 2006.

The live webcast will begin at 10:00 a.m. Pacific Time on June 2, 2006. The webcast can be accessed on Genentech's web site at and will be archived and available for replay until 5:00 p.m. Pacific Time on June 9, 2006. A telephonic replay will also be available beginning at 1:00 p.m. Pacific Time on June 2, 2006 through 5:00 p.m. Pacific Time on June 9, 2006. Access numbers for this replay are: 1-800-642-1687 (U.S./Canada) and 1-706-645-9291 (international); Conference ID number is 9427739.

About Genentech

Founded 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies. The company has headquarters in South San Francisco, Calif., and is listed on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit

Media Contact: Dawn Kalmar 650-225-5873 Investor Contact: Diane Schrick 650-225-1599

Genentech, Inc.

CONTACT: media, Dawn Kalmar, +1-650-225-5873, or investors, Diane Schrick,+1-650-225-1599, both of Genentech

Back to news